Systemic Lupus Erythematosus Treatment Market
Systemic Lupus Erythematosus Treatment Market Size was valued at USD 2.92 Billion in 2023. The Global Systemic Lupus Erythematosus Treatment industry is projected to grow from USD 3.16 Billion in 2024 to USD 6.14 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.64% during the forecast period (2024 - 2032).
Systemic lupus erythematosus is a disease that causes inflammation in connective tissues, like the lining of blood vessels and cartilage. Systemic lupus erythematosus medication includes nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and corticosteroids amongst others. Early Systemic lupus erythematosus diagnosis and treatment can help to reduce the adverse effects of SLE and improve the chances of having a better life. SLE treatment currently includes administering drugs from four categories, namely corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials, and Immunosuppressive agents and immune modulators.
Systemic Lupus Erythematosus Treatment Market Influencer
Research and development for the launch of drugs, by key players, for the treatment of systemic lupus erythematosus.
Market Drivers
- High prevalence & incidence of systemic lupus erythematosus: The worldwide prevalence of systemic lupus erythematosus in 2018 was estimated to be 150 per 100,000 individuals with an incidence of around 1 to 10 per 100,000 persons per year.
- Product launches by key players
- Strong product pipeline: As of the third quarter of the year 2019, there were around 170 ongoing clinical trials on systemic lupus erythematosus (SLE).
- Increasing awareness regarding systemic lupus erythematosus
Market Restraints
- Stringent regulatory policies
- Side effects of medications
Systemic Lupus Erythematosus Treatment Market Segmentation
Systemic Lupus Erythematosus Treatment Treatment Insights
- Corticosteroids: SLE treatment involves the use of corticosteroids, which inhibits the immune system from attacking the healthy cells of the body. Prednisone is the most frequently prescribed corticosteroid for the treatment of systemic lupus erythematosus.
- Nonsteroidal anti-inflammatory drugs (NSAIDs): This class of drugs decreases pain, reduces fever, and decreases inflammation. In around 80% of the cases, systemic lupus erythematosus medication involves the use of Nonsteroidal anti-inflammatory drugs (NSAIDs).
- Antimalarials: Although initially antimalarials were used to treat malaria, it was later found that these drugs help reduce joint and muscle pain, inflammation of the lining of the lungs and heart, fatigue, and other symptoms of lupus. New drug approvals are expected to drive the growth of this segment. For instance, in July 2018, Lupin received approval from the US Food and Drug Administration (FDA) for its generic version of antimalarial Plaquenil.
- Immunosuppressive agents and immune modulators: In specific cases, immunosuppressive agents can be used to suppress the overactive immune response. The increasing demand for drugs is expected to drive the growth of this segment. For instance, in 2018, sales of ballista (an immunosuppressant drug) increased by 24% in the US as compared to that in 2017.
Systemic Lupus Erythematosus Treatment Route of Administration Insights
- Oral: This segment generally involves tablets and capsules for the treatment of systemic lupus erythematosus.
- Intravenous: This category includes drugs administered via veins of the patient and has shown a faster effect as compared to drugs administered via oral route.
- Subcutaneous: Drugs injected under the skin, generally using a needle and syringe, are included under this category.
Systemic Lupus Erythematosus Treatment Distribution Channel Insights
- Hospital Pharmacies: Since patients admitted to hospitals prefer hospital pharmacies for purchasing prescribed drugs, and due to an increase in the number of hospitals, hospital pharmacies segment is expected to hold the largest share in the year 2018.
- Retail Pharmacies: The segment is expected to hold the second-largest systemic lupus erythematosus treatment market share.
- Online Pharmacies: It is expected to be the fastest-growing segment during the forecast period as increasing awareness regarding E-commerce has resulted in a growing trend for purchasing medicines online.
Systemic Lupus Erythematosus Treatment Region Insights
- Americas: Holds the largest systemic lupus erythematosus treatment market share due to high healthcare expenditure and the presence of key market players.
- Europe: The second-largest regional market of systemic lupus erythematosus treatment due to increasing research and measures taken for SLE management.
- Asia-Pacific: The fastest-growing regional systemic lupus erythematosus treatment market, due to increasing awareness regarding systemic lupus erythematosus treatment and increasing population affected by SLE.
- Middle East & Africa: The smallest market of systemic lupus erythematosus treatment due to limited healthcare infrastructure and lack of awareness regarding systemic lupus erythematosus treatment options.
Industry NewsNovember 2023, GlaxoSmithKline (GSK) announces that it has received FDA approval for its new drug, Benlysta (belimumab), for the treatment of adults with SLE who are receiving standard therapy. Benlysta is a monoclonal antibody that targets B cells, a type of white blood cell that plays a role in SLE. In clinical trials, Benlysta was shown to reduce the frequency of SLE flares and improve quality of life.AstraZeneca announces that it has launched a new clinical trial of its new drug, anifrolumab, for the treatment of adults with SLE. Anifrolumab is a type I interferon receptor antagonist that blocks the activity of interferon, a protein that is thought to play a role in SLE. The clinical trial will evaluate the safety and efficacy of anifrolumab in patients with SLE who have not responded to other treatments.Eli Lilly and Company announces that it has submitted a New Drug Application (NDA) to the FDA for its new drug, miriquinimod, for the treatment of adults with SLE. Miriquinimod is a small molecule that inhibits the activity of IRAK4, a protein that is thought to play a role in SLE. In clinical trials, miriquinimod was shown to reduce the frequency of SLE flares and improve quality of life.
September 2023, Several companies announce new partnerships to develop and commercialize new SLE treatments. These partnerships aim to develop new treatments that can be used to improve the lives of people with SLE.A new study published in the journal Arthritis & Rheumatology finds that a new type of immunotherapy may be effective in treating SLE. The study found that the immunotherapy was able to reduce inflammation and improve quality of life in patients with SLE who had not responded to other treatments.Another study published in the journal Lupus found that a new type of targeted therapy may be effective in treating SLE. The study found that the targeted therapy was able to reduce inflammation and improve kidney function in patients with SLE.
Systemic Lupus Erythematosus Treatment Market Key Players
- Sanofi (France)
- Hoffmann-La Roche Ltd (Switzerland)
- Novartis AG (Switzerland)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- AstraZeneca (UK)
- Eli Lilly and Company (US)
- Bristol-Myers Squibb Company (US)
- Amgen Inc. (US)
- Anthera (US)
- Johnson & Johnson Services, Inc. (US)
| Report Attribute/Metric |
Details |
| Â Â Market Size |
  USD 6.14 Billion |
| Â Â CAGR |
  8.64% |
| Â Â Base Year |
  2021 |
| Â Â Forecast Period |
  2024 - 2032 |
| Â Â Historical Data |
  2020 |
| Â Â Forecast Units |
  Value (USD Billion) |
| Â Â Report Coverage |
  Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Â Â Segments Covered |
  By Treatment, Route of Administration, Distribution Channel |
| Â Â Geographies Covered |
  North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Â Â Key Vendors |
  Sanofi (France), Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), AstraZeneca (UK), Eli Lilly and Company (US), Bristol-Myers Squibb Company (US), Amgen Inc. (US), Anthera (US), Johnson & Johnson Services, Inc. (US) |
| Â Â Key Market Opportunities |
  Joint ventures, strategic alliances, mergers and acquisitions and new product developments |
| Â Â Key Market Drivers |
 Product launches by key players Increasing awareness regarding systemic lupus erythematosus Strong product pipeline |
Systemic Lupus Erythematosus Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
systemic lupus erythematosus treatment market is projected grow at approximately 8.64% CAGR during the assessment period (2024-2032).
The valuation of the global systemic lupus erythematosus treatment market is estimated to increase to USD 6.14 Billion by the end of 2032.
The Immunosuppressive agents & immune modulators segment by treatment type holds the majority shares in the global systemic lupus erythematosus treatment market.
North America holds the largest share in the global systemic lupus erythematosus treatment market, followed by Europe and the Asia Pacific, respectively.
F. Hoffmann-La Roche Ltd (Switzerland), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Pfizer Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Amgen Inc. (US), Johnson & Johnson Services, Inc. (US), and Anthera (US), are some of the major players operating in the global systemic lupus erythematosus treatment market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
